EUVIMEDEUVIMED entdecken
Crossref

Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage

Saumya Ranjan Satrusal, Arpita Banerjee, Arpon Biswas, Gaurava Srivastava, Indranil Chatterjee, Muqtada Ali Khan, Biswajit Mandal, Kiran Tripathi, Abhipsa Sinha, Ayushi Verma, Priyanka Rai, Mahmood Akbar und 7 weitere

Molecular Therapy · 2026-11 · 34 (11) · 6513-6560

DOI: 10.1016/j.ymthe.2026.08.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026-11. Verfasst von Saumya Ranjan Satrusal und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Division, CSIR-Central Drug Research Institute (CDRI), Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), G…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Triple Negative Breast Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Globally, triple-negative breast cancer (TNBC) has a huge unmet medical need, as it has limited targeted therapeutic options. However, it has well-known therapeutic vulnerabilities for selective inhibition of pathways such as EGFR, mTOR, PARP, enhancer of zeste homolog 2 (EZH2), PD1-PDL1, etc. Analysis of publicly available databases clearly suggests that concomitant EZH2 and EGFR overexpression results in poor survival of patients with TNBC compared to their individual overexpression, underscoring the strong rationale for dual-targeted therapeutic intervention. Herein, potent, tumor cell-selective chemical probes were designed and synthesized that simultaneously bind to both EZH2 and EGFR and inhibit their pro-tumorigenic functions in TNBC. Structure-activity relationship (SAR)-driven optimized lead molecule S-023-0996 (41a) proficiently binds and inhibits dual targets, dampening tumor cell proliferation, migration, and invasion in vitro with superior efficacy and safety than individual drug combinations (EZH2 inhibitor tazemetostat and EGFR inhibitor gefitinib). Mass spectrometry-based proteomic profiling revealed that translation inhibition is a key differentiating factor for achieving robust anti-tumor effects of S-023-0996. S-023-0996 has favorable pharmacokinetic properties and inhibits tumor growth and metastasis in vivo more efficiently than comparator drug combinations in preclinical TNBC models. Our results represent the discovery of a first-in-class dual EZH2-EGFR inhibitor and establish the possibility of targeting two TNBC vulnerabilities together with a single chemical entity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinTriple Negative Breast NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsHumansErbB ReceptorsAnimalsFemaleCell Line, TumorCell ProliferationMiceXenograft Model Antitumor AssaysStructure-Activity RelationshipMolecular Targeted TherapyCell MovementGene Expression Regulation, NeoplasticBenzamidesBiphenyl CompoundsMorpholinesPyridones

Stichwörter der Autor:innen

EGFREZH2TNBC therapydual inhibitorprotein translationsmall-molecule inhibitor

Substanzen

Enhancer of Zeste Homolog 2 ProteinErbB ReceptorsEZH2 protein, humanAntineoplastic AgentsEGFR protein, humanProtein Kinase InhibitorstazemetostatBenzamidesBiphenyl CompoundsMorpholines

Autor:innen und Institutionen

  • Cancer Biology Division, CSIR-Central Drug Research Institute (CDRI), Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
  • Medicinal and Process Chemistry Division, CDRI, Lucknow 226031, India.
  • Pharmaceutics and Pharmacokinetics Division, CDRI, Lucknow 226031, India.
  • Cancer Biology Division, CSIR-Central Drug Research Institute (CDRI), Lucknow 226031, India.
  • Toxicology and Experimental Medicine Division, CDRI, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
  • Medicinal and Process Chemistry Division, CDRI, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Satrusal, S. R., Banerjee, A., Biswas, A., Srivastava, G., Chatterjee, I., Khan, M. A., Mandal, B., Tripathi, K., Sinha, A., Verma, A., Rai, P., Akbar, M., Kumar, S., Chatterjee, S., Singh, K., Nazir, A., Bhatta, R. S., Panda, G., & Datta, D. (2026). Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular Therapy, 34(11), 6513-6560. https://doi.org/10.1016/j.ymthe.2026.08.034

Vancouver

Satrusal SR, Banerjee A, Biswas A, Srivastava G, Chatterjee I, Khan MA, et al. Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular Therapy. 2026;34(11):6513-6560. doi:10.1016/j.ymthe.2026.08.034

BibTeX
@article{Satrusal2026,
  author = {Satrusal, Saumya Ranjan and Banerjee, Arpita and Biswas, Arpon and Srivastava, Gaurava and Chatterjee, Indranil and Khan, Muqtada Ali and Mandal, Biswajit and Tripathi, Kiran and Sinha, Abhipsa and Verma, Ayushi and Rai, Priyanka and Akbar, Mahmood and Kumar, Shivansh and Chatterjee, Sohini and Singh, Kulranjan and Nazir, Aamir and Bhatta, Rabi Sankar and Panda, Gautam and Datta, Dipak},
  title = {Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage},
  journal = {Molecular Therapy},
  year = {2026},
  volume = {34},
  number = {11},
  pages = {6513--6560},
  doi = {10.1016/j.ymthe.2026.08.034}
}
Kostenlos starten →